Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success ...

Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations ...

ZyVersa announces pipeline ... innovative product pipeline online. ZyVersa is developing two first-in-class drug candidates, which positions the company as an innovator in the biopharmaceutical ...

mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing ...

We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company,” said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. “We have ...

(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company ... pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study ...

Insmed (NASDAQ:INSM) Incorporated, a U.S. biopharmaceutical company specializing ... as investors weigh the potential of its product pipeline against current financial performance.

(Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary ... s financial position to continue advancing its product candidates, expectations about cash ...